SCHEDULE 13G/A: Investment Funds Disclose Passive 4.9% Stake in Theriva Biologics

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a passive 4.9% beneficial ownership stake in Theriva Biologics, Inc. as of December 31, 2024.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. (Reporting Persons) jointly reported beneficial ownership of 146,136 shares of Theriva Biologics, Inc. common stock.
• This represents 4.9% of the company's outstanding common stock.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and exercises shared voting and dispositive power over these shares.
• The reported shares include those issuable upon the exercise of warrants, which are subject to a 4.99% beneficial ownership limitation.
• As of November 8, 2024, Theriva Biologics, Inc. had 2,782,449 shares outstanding.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment intent.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory filing reporting beneficial ownership and does not convey positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• A significant institutional investor (CVI Investments, Inc., managed by Heights Capital Management, Inc.) maintains a stake in Theriva Biologics, indicating continued interest.
• The ownership is passive, suggesting no immediate intent to influence or control the company's operations.

Negatives

• The filing itself does not contain negative financial or operational information about Theriva Biologics, Inc.

Risks

• The beneficial ownership includes shares issuable upon the exercise of warrants, which could lead to dilution if exercised, though the document specifies a 4.99% beneficial ownership limit on exercise.

Future Outlook

The document is a beneficial ownership report and does not contain forward-looking statements or guidance regarding Theriva Biologics, Inc.'s future performance or strategic direction.

Industry Context

This Schedule 13G filing reflects a passive investment by institutional funds in a biologics company. Such filings are routine disclosures for investors holding less than 5% of a company's shares with no intent to control, and do not typically provide insights into broader industry trends or competitive landscapes.

Comparison to Industry Standards

• This document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that allows for a direct comparison of Theriva Biologics' operational or financial results against industry benchmarks or specific comparable companies/projects.
• The 4.9% passive stake is a common investment threshold for institutional investors seeking to avoid more stringent reporting requirements associated with larger, active stakes.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive institutional investor's stake in the company.

Next Steps

• The document is a regulatory filing and does not outline specific future actions, events, or milestones for Theriva Biologics, Inc. or the reporting persons beyond the ongoing passive investment.

Key Dates

Keywords

Theriva Biologics, CVI Investments, Heights Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Passive Investment, SEC Filing, Biologics